Evidence map›Paper›PMID 27908751›Full record

ArticleBioorganic & medicinal chemistry2017

Enhanced potency of bivalent small molecule gp41 inhibitors.

Vladimir Sofiyev, Hardeep Kaur, Beth A Snyder, Priscilla A Hogan, Roger G Ptak, Peter Hwang, Miriam Gochin

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Vladimir SofiyevDepartment of Basic Sciences, Touro University-California, Vallejo, CA 94592, United States.
Hardeep KaurDepartment of Basic Sciences, Touro University-California, Vallejo, CA 94592, United States.
Beth A SnyderSouthern Research Institute, 431 Aviation Way, Frederick, MD 21701, United States.
Priscilla A HoganSouthern Research Institute, 431 Aviation Way, Frederick, MD 21701, United States.
Roger G PtakSouthern Research Institute, 431 Aviation Way, Frederick, MD 21701, United States.
Peter HwangDepartment of Biophysics and Biochemistry, University of California San Francisco, CA 94143, United States.
Miriam GochinDepartment of Basic Sciences, Touro University-California, Vallejo, CA 94592, United States; Department of Pharmaceutical Chemistry, University of California San Francisco, CA 94143, United States. Electronic address: miriam.gochin@tu.edu.
Southern Research Institute · USTouro University California · USUniversity of California, San Francisco · US

Funding

XRAY CRYSTALLOGRAPHIC STRUCTURE ANALYSIS: PROTEIN SORTINGP41RR001081 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 1985 to 2011
$17.6M
Structure-based discovery and development of HIV-1 gp41 fusion inhibitorsR01GM087998 · NIGMS · TOURO UNIVERSITY OF CALIFORNIA · PI GOCHIN, MIRIAM · 2010 to 2013
$1.1M
Mechanism of indole compounds as HIV fusion inhibitorsR21AI122847 · NIAID · TOURO UNIVERSITY OF CALIFORNIA · PI GOCHIN, MIRIAM · 2016 to 2017
$393k
Rational design of indole compounds as HIV fusion inhibitorsR21AI093243 · NIAID · TOURO UNIVERSITY OF CALIFORNIA · PI GOCHIN, MIRIAM · 2011 to 2012
$385k
NCRR NIH HHS P41 RR001081NIAID NIH HHS R21 AI093243NIAID NIH HHS R21 AI122847NIGMS NIH HHS R01 GM087998
6 · The paper itself

Abstract

Low molecular weight peptidomimetic inhibitors with hydrophobic pocket binding properties and moderate fusion inhibitory activity against HIV-1 gp41-mediated cell fusion were elaborated by increasing the available surface area for interacting with the heptad repeat-1 (HR1) coiled coil on gp41. Two types of modifications were tested: 1) increasing the overall hydrophobicity of the molecules with an extension that could interact in the HR1 groove, and 2) forming symmetrical dimers with two peptidomimetic motifs that could potentially interact simultaneously in two hydrophobic pockets on the HR1 trimer. The latter approach was more successful, yielding 40-60times improved potency against HIV fusion over the monomers. Biophysical characterization, including equilibrium binding studies by fluorescence and kinetic analysis by Surface Plasmon Resonance, revealed that inhibitor potency was better correlated to off-rates than to binding affinity. Binding and kinetic data could be fit to a model of bidentate interaction of dimers with the HR1 trimer as an explanation for the slow off-rate, albeit with minimal cooperativity due to the highly flexible ligand structures. The strong cooperativity observed in fusion inhibitory activity of the dimers implied accentuated potency due to the transient nature of the targeted intermediate. Optimization of monomer, dimer or higher order structures has the potential to lead to highly potent non-peptide fusion inhibitors by targeting multiple hydrophobic pockets.

Indexed as

Binding SitesCell FusionHeLa CellsHIV Envelope Protein gp41HIV Fusion InhibitorsHumansKineticsModels, ChemicalPeptidomimeticsHIV Envelope Protein gp41HIV Fusion InhibitorsPeptidomimeticsBivalent inhibitorsCooperativityFluorescenceFusion inhibitionHIV-1 gp41Hydrophobic pocketKineticsPeptidomimetic inhibitorsSurface plasmon resonance

Identifiers

PMID27908751
PMCPMC5260928
OpenAlexW2549971631

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.